Andrew W. Pippas, MD

Dr. Andrew W. Pippas

Claim this profile

John B Amos Cancer Center

Studies Breast Cancer
Studies Breast cancer
18 reported clinical trials
52 drugs studied

Area of expertise

1

Breast Cancer

Andrew W. Pippas has run 6 trials for Breast Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage I
2

Breast Cancer

Andrew W. Pippas has run 6 trials for Breast cancer. Some of their research focus areas include:

Stage I
Stage II
PD-L1 positive

Affiliated Hospitals

Image of trial facility.

John B. Amos Cancer Center

Image of trial facility.

IACT Health

Clinical Trials Andrew W. Pippas is currently running

Image of trial facility.

Nanosomal Docetaxel

for Triple Negative Breast Cancer

This trial tests a new, safer form of the cancer drug docetaxel, called Nanosomal Docetaxel Lipid Suspension (NDLS), in patients with advanced or spreading triple-negative breast cancer. NDLS aims to reduce side effects by using tiny fat particles. The drug works by stopping cancer cells from dividing and growing. Docetaxel is a widely used chemotherapy drug, and newer formulations like Nanosomal Docetaxel Lipid Suspension (NDLS) aim to improve its efficacy and reduce toxicity.

Recruiting

4 awards

Phase 3

13 criteria

Image of trial facility.

Repotrectinib

for Solid Tumors

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

Recruiting

1 award

Phase 1 & 2

7 criteria

More about Andrew W. Pippas

Clinical Trial Related

9 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Andrew W. Pippas has experience with

  • Pembrolizumab
  • Prednisone
  • Repotrectinib (TPX-0005)
  • EndoPredict®
  • Ladiratuzumab Vedotin
  • Nanosomal Docetaxel Lipid Suspension

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Andrew W. Pippas specialize in?

Is Andrew W. Pippas currently recruiting for clinical trials?

Are there any treatments that Andrew W. Pippas has studied deeply?

What is the best way to schedule an appointment with Andrew W. Pippas?

What is the office address of Andrew W. Pippas?

Is there any support for travel costs?